NCT01534468View on ClinicalTrials.gov

Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Influenza A Subtype H7N7 Infection
Interventions
BIOLOGICAL

Monovalent Influenza Subvirion Vaccine, H7N7

At study entry, all participants will receive one IM injection of approximately 45 micrograms of inactivated Monovalent Influenza Subvirion Vaccine, H7N7.

Trial Locations (1)

14642

University of Rochester, Rochester

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01534468 - Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter